| Primary |
| Product Used For Unknown Indication |
41.7% |
| Cerebral Toxoplasmosis |
10.6% |
| Drug Use For Unknown Indication |
7.6% |
| Hiv Infection |
7.6% |
| Rheumatoid Arthritis |
3.8% |
| Pneumocystis Jiroveci Pneumonia |
3.0% |
| Pneumocystis Jirovecii Pneumonia |
3.0% |
| Tuberculosis |
3.0% |
| Hypertension |
2.3% |
| Oligodendroglioma |
2.3% |
| Pneumonia Herpes Viral |
2.3% |
| Asthma |
1.5% |
| Disseminated Tuberculosis |
1.5% |
| Extrapulmonary Tuberculosis |
1.5% |
| Herpes Simplex |
1.5% |
| Pneumocystis Jiroveci Infection |
1.5% |
| Pneumocystis Jirovecii Infection |
1.5% |
| Prophylaxis |
1.5% |
| Prophylaxis Against Transplant Rejection |
1.5% |
| Antibiotic Prophylaxis |
0.8% |
|
| Leukopenia |
10.3% |
| Toxic Epidermal Necrolysis |
10.3% |
| Gamma-glutamyltransferase Increased |
6.9% |
| Hepatic Failure |
6.9% |
| Rash Maculo-papular |
6.9% |
| Renal Failure Acute |
6.9% |
| Ventricular Arrhythmia |
6.9% |
| Agranulocytosis |
3.4% |
| Anaemia |
3.4% |
| Cytolytic Hepatitis |
3.4% |
| Eosinophil Count Increased |
3.4% |
| Febrile Neutropenia |
3.4% |
| Hyperbilirubinaemia |
3.4% |
| Lactic Acidosis |
3.4% |
| Neutropenia |
3.4% |
| No Adverse Drug Reaction |
3.4% |
| Off Label Use |
3.4% |
| Pancytopenia |
3.4% |
| Pneumocystis Jiroveci Pneumonia |
3.4% |
| Pneumocystis Jirovecii Infection |
3.4% |
|
| Secondary |
| Product Used For Unknown Indication |
27.5% |
| Hiv Infection |
11.9% |
| Hiv Test Positive |
11.0% |
| Drug Use For Unknown Indication |
7.3% |
| Prophylaxis |
4.6% |
| Prophylactic Chemotherapy |
3.7% |
| Tuberculosis |
3.7% |
| Acute Lymphocytic Leukaemia |
2.8% |
| Central Nervous System Lymphoma |
2.8% |
| Cryptococcosis |
2.8% |
| Epilepsy |
2.8% |
| Lymphoma |
2.8% |
| Pneumocystis Jiroveci Pneumonia |
2.8% |
| Pneumocystis Jirovecii Pneumonia |
2.8% |
| Staphylococcal Bacteraemia |
2.8% |
| Cytomegalovirus Infection |
1.8% |
| Hepatitis C |
1.8% |
| Hepatitis Cholestatic |
1.8% |
| Pneumonia |
1.8% |
| Anxiety |
0.9% |
|
| Thrombocytopenia |
22.2% |
| Toxic Epidermal Necrolysis |
14.8% |
| Vomiting |
14.8% |
| Pyrexia |
7.4% |
| Anaemia Macrocytic |
3.7% |
| Cytolytic Hepatitis |
3.7% |
| Lobar Pneumonia |
3.7% |
| Pneumocystis Jirovecii Infection |
3.7% |
| Rash Maculo-papular |
3.7% |
| Rash Pruritic |
3.7% |
| Tachycardia |
3.7% |
| Toxic Skin Eruption |
3.7% |
| Transaminases Increased |
3.7% |
| Urticaria |
3.7% |
| Ventricular Arrhythmia |
3.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
23.0% |
| Hiv Infection |
22.5% |
| Drug Use For Unknown Indication |
15.1% |
| Hodgkin's Disease |
5.7% |
| Acute Myeloid Leukaemia |
3.9% |
| Prophylaxis |
3.9% |
| Diarrhoea |
2.7% |
| Hypertension |
2.7% |
| Chronic Myeloid Leukaemia |
2.5% |
| Multiple Myeloma |
2.2% |
| Epilepsy |
2.0% |
| Angina Pectoris |
1.9% |
| Mitochondrial Toxicity |
1.9% |
| Infection Prophylaxis |
1.7% |
| Plasma Cell Myeloma |
1.7% |
| Ovarian Epithelial Cancer |
1.4% |
| B-cell Lymphoma |
1.3% |
| Hepatic Cirrhosis |
1.3% |
| Oral Candidiasis |
1.3% |
| Pain |
1.3% |
|
| Myalgia |
10.3% |
| Drug Interaction |
7.4% |
| Myocardial Infarction |
7.4% |
| Sepsis |
7.4% |
| Thrombocytopenia |
7.4% |
| Vomiting |
7.4% |
| Weight Decreased |
5.9% |
| Capillary Leak Syndrome |
4.4% |
| Pancreatic Insufficiency |
4.4% |
| Pyrexia |
4.4% |
| Rash Morbilliform |
4.4% |
| Renal Failure Acute |
4.4% |
| Urticaria |
4.4% |
| Epilepsy |
2.9% |
| Febrile Neutropenia |
2.9% |
| Hyperthyroidism |
2.9% |
| Immune Reconstitution Syndrome |
2.9% |
| Malaise |
2.9% |
| Mucosal Inflammation |
2.9% |
| Overdose |
2.9% |
|
